In the United States, Europe and in many other countries, MabThera is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. MabThera is also approved for the treatment of adults in auto-immune diseases: severe active rheumatoid arthritis, pemphigus vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).
In the pediatric population, MabThera/Rituxan is approved in the United States, Europe and other countries for the treatment of previously untreated DLBCL, Burkitt lymphoma/leukemia or Burkitt-like lymphoma as well as GPA/MPA.
In the United States, Japan and Canada, MabThera is marketed as Rituxan.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.